Proprietary pooled human umbilical cord-derived mesenchymal stromal cell (hucMSC) platform; off-the-shelf, allogeneic, intravenous cell therapy with anti-inflammatory and immunomodulatory properties; initial focus on RDEB and other complex inflammatory diseases; platform enables indication-specific product tuning

DN-TNF · Xencor

Dominant negative tumor necrosis factor variant protein platform covering pegylated DN-TNF variants XPro1595 and INB03; targets neuroinflammation via selective neutralization of soluble TNF; focus on neurodegenerative diseases including Alzheimer's disease

Targets: soluble TNF, sTNF

Discontinued (1)

INKmune — Myelodysplastic Syndrome · terminated further enrollment in the MDS/AML trial in March 2024 due to post-Covid recruitment problems

Biotech Distilled coverage (1)

2026-07-21 INmune Bio (INMB) — Scientific Deep Dive for CORDStrom (Ebstrocel) and XPro1595, Plus the DN-TNF & NK Pipeline

Articles open on Substack. Some deep dives are subscriber-only.